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ABSTRACT
Objective To investigate if autoimmune thyroid disease
(AITD) impacts rheumatoid arthritis (RA) disease activity or
response to methotrexate.
Methods A nationwide register-based cohort study of 9
004 patients with new-onset RA from the Swedish
Rheumatology Quality Register year 2006–2016, with
linkage to other nationwide registers to identify comorbidity
with AITD defined as thyroxine prescription before RA
diagnosis, excluding non-autoimmune causes. We
compared RA disease activity using 28-joint Disease Activity
Score (DAS28) and its components, and EULAR response,
between patients with and without AITD, using logistic
regression.
Results At diagnosis, patient reported outcome measures
(PROMs; patient global, Health Assessment Questionnaire
Disability Index and pain) but not objective disease activity
measures (erythrocyte sedimentation rate and swollen joint
count) were significantly higher (p<0.05 for all PROMs)
among RA patients with AITD compared with those without.
The level of DAS28 was 5.2 vs 5.1. By contrast, AITD had
little influence on EULAR response to methotrexate at 3
months (OR of non/moderate response=0.95, 95% CI 0.8 to
1.1), nor at 6 months. When stratified by age, however, AITD
was more common among EULAR non/moderate
responders at 3 and 6 months in patients below 45 years
resulting in ORs of non/moderate response of 1.44
(0.76–2.76) and 2.75 (1.04–7.28).
Conclusion At diagnosis, RA patients with concomitant
AITD score worse on patient reported but not on objective RA
disease activity measures, while DAS28 was only marginally
elevated. The overall chance of achieving a EULAR good
response at 3 or 6 months remains unaffected, although
among a limited subgroup of younger patients, AITD may be
a predictor for an inferior primary response.
INTRODUCTION
Autoimmune thyroid disease (AITD), includ-
ing hypothyroidism and hyperthyroidism of
autoimmune origin, is the most common
autoimmune disease in the general popula-
tion, with a prevalence of approximately 5%.1
The prevalence of AITD is increased in
patients with rheumatoid arthritis (RA),
making AITD one of the most common co-
morbid conditions in RA.2–9 The underlying
pathogenicmechanisms of the co-occurrence
between AITD and RA are not well under-
stood, but polymorphisms in genes involved
in the regulation of T-cell response may play
a key role.1
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What is already known about this subject?
► Autoimmune thyroid disease (AITD) increases the
risk of RA. With a prevalence of approximately
10%, AITD is also one of the most common co-
morbid conditions in patients with RA. Yet, it is less
well understood whether AITD affects also the RA
phenotype and response to anti-rheumatic
therapies.
What does this study add?
► In this Swedish cohort study of early RA patients, the
disease activity and treatment response to
methotrexate as first-line therapy was compared
between patients with early RA and AITD vs RA
patients without this comorbidity.
► AITD, present among 11% of all the patients with RA,
was linked to worse subjective but not to worse
objective measures of RA disease activity.
However, AITD did not impact response to
treatment, with one exception, young patients with
both RA and AITD, who were less likely to achieve
a good response to methotrexate.
How might this impact on clinical practice?
► Through worse subjective RA disease activity
components, concomitant AITD influences the
phenotypic presentation of RA and the observed
composite treatment response measures used in
clinical practice.
► When treating and evaluating early RA patients with
concomitant AITD, it is of importance to pay attention
not only to the overall disease activity and response
measures such as DAS28, but to unpick its
components.
Rheumatoid arthritis
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In contrast to the well-established increased occurrence
of RA in patients with AITD10–12 and increased occur-
rence of AITD in patients with RA,12 13 considerably less
is known about the impact of AITD on the phenotypic
presentation of RA, and on its impact on response to anti-
rheumatic therapies. Previous findings indicate an associa-
tion between hypothyroidism and higher macrophage
inflammatory response with release of pro-inflammatory
cytokines (interleukin-1 (IL-1), IL-6 and tumour necrosis
factor-α).14 15 Hypothyroidism may cause symptoms such
as fatigue, myalgia and arthralgia that may also occur in
RA.16 One study, of 52 prevalent RA patients, reported
a correlation between hypothyroidism and higher disease
activity.17 Another study, based on 439 prevalent RA
patients from a Danish registry and based on 28-joint
Disease Activity Score-C reactiveprotein (DAS28-CRP)
scores reported, somewhat contradictory, no significant
difference in RA disease activity at diagnosis but
a reduced chance of response to anti-rheumatic drugs at
4 months from treatment initiation.18 These findings call
for a more detailed assessment of how AITD impacts the
presentation and evolution of RA disease activity, as mea-
sured by different types of metrics, and also of how AITD
affects the observed RA treatment response.
The objectives of this study were therefore to investi-
gate, in a study population large enough to allow for
assessments of differences across subgroups of patients,
whether and how concomitant AITD impacts patient-
related and physician-related measures of disease activity,
at the time of RA diagnosis and at 3-month and 6-month
follow-up visits, and also how AITD affects the response to
first-line treatment with methotrexate. In addition to
overall effects, we investigated variations in RA disease
presentation and treatment response across subsets as
defined by RA serological status, sex and age.
PATIENTS AND METHODS
Setting and data sources
The setting and data sources used for this study have been
described in detail previously.19 Following RA diagnosis,
the majority of Swedish RA patients start methotrexate as
their first disease-modifying anti-rheumatic drugs
(DMARD). The dose of methotrexate is increased up to
20 mg per week. Patients are followed-up according to an
early RA treatment guideline (see eText 1 in online sup
plementary material). In brief, we used data from the
following data sources: The Swedish Rheumatology Quality
Register (SRQ) is a nationwide clinical register of patients
with RA. It is used in clinical practice since 1996 to follow
patients’ disease course longitudinally, including anti-
rheumatic treatments, health-related variables and the
physicians and patients’ assessment of disease activity.
The current coverage is close to 90% of all new-onset
RA. To be registered as ‘early RA’ in the SRQ, the patient
must fulfill the American College of Rheumatology cri-
teria for RA20 and/or the American College of Rheuma-
tology/European League Against Rheumatism
classification criteria21 with a RA symptom duration less
than 12 months. The Swedish prescribed drug register (PDR)
started in 2005 and includes information on all dispensa-
tions of prescribed drugs in Sweden. The Swedish cancer
register started in 1958 and includes all incident diagnoses
of cancer and is mandatory for all clinicians.
Swedish residents are assigned a personal identification
number, unique for each individual, which enables link-
age of individual-level data across nationwide registers,
and the current study is based on a linkage between the
registers described above. The Stockholm Regional Ethics
Committee approved this study (DNR 2015/1844-31/2).
Study population
We identified all patients included as early RA in the SRQ
between January 1, 2006 and December 31, 2016 (n=13
187). The current analyses are based on those 9 004
patients (6 072 women and 2 932 men; mean±SD age,
65.8±15.0 years) who started methotrexate monotherapy
at diagnosis and who had disease activity measures regis-
tered both at start and at follow-up visits to allow for
response analyses, see table 1 and online supplementary
figure 1. The occurrence of AITD among excluded
patients did not differ substantially from those included.
Occurrence of AITD
The vast majority of patients treated with thyroxine sub-
stitution have an underlying AITD, once non-
autoimmune causes for treatment are excluded.19 22 23
We therefore defined AITD as filling a prescription of
thyroid hormone substitution therapy, identified
through linkage to the PDR 2005 through 2016. Patients
with a prescription of iodine-containing drugs (inter-
feron-alpha, lithium and amiodarone) or a previous
thyroid cancer, based on linkage to the PDR and the
Swedish Cancer Register were excluded (see eText 2
for the ATC and ICD codes used and online supplemen
tary figure 1). Prevalent AITD was defined as a thyroxine
prescription in the PDR already before the diagnosis
of RA.
RA disease activity and treatment response
We used DAS28-erythrocyte sedimentation rate (ESR) to
define RA disease activity and the change in RA disease
activity between visits, ΔDAS28-ESR, at the 3-month or
6-month visit after treatment start (±1–2 months). If the
patient had several visits during the specified time period,
we used the visit closest to 3 and 6 months from the time
of diagnosis, respectively.
Response states were defined as non, moderate and
good responder based on the EULAR DAS28-ESR
response criteria.24 In addition, a patient was defined as
non-responder if switching frommethotrexate to another
DMARD at or before the follow-up visit, irrespective of
EULAR response status. Below, DAS28-ESR will be
referred to as DAS28.
In addition to the patient global Visual Analogue Scale
(VAS) (below referred to as ‘patient global’), we used the
RMD Open
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following patient-reported disease activity variables:
Health Assessment Questionnaire Disability Index
(HAQ) and VAS pain (referred to as ‘pain’).25
Statistical methods
We first examined the association between prevalent
AITD and RA disease activity at diagnosis (measured as
DAS28, its individual components, HAQ and pain) using
linear regression adjusted for sex and age.
Second, for each RA disease activity measure, we
examined the association between prevalent AITD
and the change (delta) of the parameter between
the RA diagnosis and the 3-month and 6-month, fol-
low-up visits, respectively, using linear regression, with
models adjusted for age and sex, as well as addition-
ally adjusted for the baseline value of the parameter in
question.
Third, we examined the association between AITD and
response to methotrexate after 3 and 6 months from
treatment initiation by comparing the proportions of
EULAR DAS28 good responders versus moderate or non-
responders, using logistic regression adjusted for age and
sex. In additional models, we also adjusted for HAQ, use
of oral steroids and smoking.
All analyses were performed by using SAS version 9.4
(SAS Institute).
Because of missing values (approximately 20%, see
eText 3 in online supplementary material) on the DAS28
variables, we performed two separate analyses, one for all
patients with a 3-month and/or 6-month visit (n=6 025 and
n=4 996) and one for the patients with complete informa-
tion on DAS28 variables at the same time points (n=4 831
and n=4 010; online supplementary figure 1). The propor-
tions of patients receiving methotrexate or prednisolone
at start and 3/6 months and response status were similar
for the patients with versus without complete information
on DAS28. The characteristics of patients with complete
information on DAS28 are shown in table 2. We further
imputed response status for those patients who had miss-
ing information on EULAR DAS28 response by multiple
imputations (see eText 3 in online supplementary mate
rial). We similarly imputed data on HAQ and smoking.
RESULTS
Among the 9 004 RA patients who were included in
the study, the prevalence of AITD was 11% (n=1 003)
(table 1). As expected, the proportion of women was
higher in patients with AITD compared with those with-
out (88% vs 65%), while the mean±SD age did not differ
substantially between the groups (68±14 vs 65±15 years).
AITD and its association with disease activity at RA diagnosis
and at 3/6 months
At RA diagnosis, the patient-reported disease activity mea-
sures (patient global, HAQ and pain) were significantly
higher among RA patients with AITD compared with
those without: patient global 57 vs 52, mean difference
+3.6, HAQ 1.2 vs 1.0, mean difference +0.08, pain 58 vs 53,
mean difference +3.8. The DAS28 levels were clinically and
statistically similar in patients with versus without AITD (5.2
vs 5.1, mean difference +0.1), see table 3. Among the indi-
vidual DAS28 components, ESR, swollen joint count and
tender joint count were not statistically higher in patients
with versus without AITD, table 3. At 3 and 6 months, there
were only small numerical and no statistical differences in
all of the above measures between patients with versus with-
out AITD (table 3 and online appendix table I).
Table 1 Baseline characteristics of 9004 RA patients












































Unspecified RA 229 (2.5) 37 (3.7) 192 (2.4)
Duration of symptoms
(months)
5.5 (3.3) 5.5 (3.3) 5.5 (3.3)
Year of inclusion in SRQ
2006 690 (7.7) 68 (6.8) 622 (7.8)
2007 699 (7.8) 65 (6.5) 634 (7.9)





2010 812 (9.0) 94 (9.4) 718 (9.0)
2011 835 (9.3) 94 (9.4) 741 (9.3)
2012 891 (9.9) 113
(11.3)
778 (9.7)
2013 872 (9.7) 102
(10.2)
770 (9.6)
2014 834 (9.3) 95 (9.5) 739 (9.2)
2015 846 (9.4) 92 (9.2) 754 (9.4)
2016 864 (9.6) 110
(11.0)
754 (9.4)
*Values are the number (%).
†First thyroxine prescription before RA diagnosis. Non-
autoimmune cause for thyroxine prescription not excluded.
‡Mean (± SD years).
§According to the ICD 10 registered, assessed at the time of
inclusion in the SRQ.
AITD, autoimmune thyroid disease; RA, rheumatoid arthritis.
Rheumatoid arthritis
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AITD and change in RA disease activity between baseline and
3/6 months
Comparing baseline and 3 months, patients with (vs
without) AITD had a more pronounced decrease in
patients global (−28 vs −24), whereas the decrease in
pain, HAQ and other DAS28 components was similar
(table 4). The change in DAS28 components is dis-
played in figure 1. Comparing baseline and 6
months, there were only small numerical differences,
for all parameters under study (table 4). When
adjusting also for the baseline value of the
parameter under study, the difference in delta
patients global for those with versus without AITD
disappeared, but for all other parameters, the pat-
tern of small differences remained (online appendix
table II).
In analyses stratified by age at RA diagnosis, the ten or
so percent of all patients who were below 45 years of age
displayed a somewhat different pattern, with AITD linked
to a slightly lower disease activity at baseline, though none
of these differences reaches statistical significance
(online appendix tables III and IV).
Table 3 DAS28 parameters at baseline and at 3-month follow-up visit for RA patients in the Swedish Rheumatology Quality
Register (SRQ), 2006–2016
Patients with complete information at 3-month
follow-up visit (n=4 831)







































































For each of the seven variables named in the first column and for each time point, the estimate (β) was provided by a linear regression model for
which the variable in the first column was the dependent variable, AITD the independent variable, and age and sex used as adjustment. The
estimate β gives themean difference (given the linear model) between the two types of patients, a positive valuemeaning that the AITD+ patients
have on average a higher value than the AITD− patients.
AITD, autoimmune thyroid disease; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.
Table 2 Characteristics of RA -patients identified in the Swedish Rheumatology Quality Register (SRQ), at baseline, 3-month
and 6-month follow-up visit*
Patientswith complete information at 3-month
follow-up visit (n=4 831)
Patientswith complete information at 6-month
follow-up visit (n=4 010)
Baseline 3-Month follow-up Baseline 6-Month follow-up
Methotrexate 4 831 (100) 4 497 (93) 4 010 (100) 3 579 (89)
Prednisolone 3 144 (65) 2 984 (62) 2 604 (65) 2 311 (58)
Response status†
Non-responders 1 382 (29) 1 576 (39)
Moderate responders 1 284 (27) 776 (19)
Good responders 2 165 (45) 1 658 (41)
*Values are the number (%).
†Response status according to EULAR response criteria. If change of DMARD at follow-up visit=non-responder.
RA, rheumatoid arthritis.
RMD Open
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Association between AITD and response to methotrexate as
first DMARD in RA
Among 7 442 RA patients starting MTX, 6 025 had
a 3-month follow up-visit and 4 996 had a 6-month visit
(see online supplementary figure 1). Disease activity
measures were registered or imputed (registered for 4
831 and imputed for 1 194 patients) at both diagnosis
(treatment initiation) and the 3-month follow-up visit.
Overall, we observed no difference in the proportion of
patients with concurrent AITD among the non/
Table 4 Changes in DAS28 parameters from baseline to 3-month and 6-month follow-up visit, among RA patients in the
Swedish Rheumatology Quality Register (SRQ)
Patients with complete information at
3-month follow-up (n=4 831)
Patient with complete information at













































































































For each of the seven variables named in the first column and for each time point, the estimate (β) was provided by a linear regression model for
which the variable in the first column was the dependent variable, AITD the independent variable, and age and sex used as adjustment. The
estimate (β) shows how differently the two types of patients were evolving between baseline and 3/6 months. For a given variable in the first
column, a positive value means that the AITD+ patients have on average evolved (decreased) more than the AITD− patients.
AITD, autoimmune thyroid disease; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.
Figure 1 Change in DAS28 components (mean) between 0 and 3 months, and EULAR DAS28-ESR response at 3 months.
DAS28-ESR, 28-joint Disease Activity Score-erythrocyte sedimentation rate.
Rheumatoid arthritis
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moderate vs good responders at the 3-month visit (11% in
both groups, see table 5). Separate analyses stratified by
sex and seropositivity yielded similar results. Similar
results were also observed using the 6-month follow-up
visit (online appendix table VI) and when restricted to
non-imputed data (online appendix tables V and VII).
Analyses stratified by age (below and above, respec-
tively, 45 years) revealed a trend towards AITD and
lower chance of good response among younger
patients at 3 months, OR, 1.44; 95% CI, 0.76 to 2.76
but not in older patients, OR, 0.92; 95% CI, 0.77 to
1.10 (table 5). At 6 months, there was a significant
association between AITD and lack of good response
among younger patients (OR 2.75; 95% CI, 1.04 to
7.28) but not for older patients (OR, 1.11; 95% CI,
0.90 to 1.37), online appendix table VI. The lack of
good response among young patients was even more
pronounced when restricted to non-imputed data
(online appendix tables V and VII).
DISCUSSION
Our results from this large study on the impact of AITD on
RA disease presentation and response, indicate that AITD
affects disease presentation at RA diagnosis, primarily
through patient-reported but not objective measures. Tak-
ing this difference into account, AITD did not seem to
affect the chance of receiving a good treatment response.
These findings underscore the need for a systematic eva-
luation of not only composite measures such as DAS28
levels but also of its individual components and additional
parameters. In contrast to this overall pattern, we noted
a somewhat different pattern of disease activity and
a stronger negative effect on treatment response, in
patients with AITD and below 45 years of age. These latter
results extend previous findings of a stronger link between
AITD and RA among younger patients (the OR for
hypothyroidism in RA patients, 18–44 years of age: 2.12,
OR among 45–69 years: 1.42, and OR 70+ years: 1.37).9
In light of the age and sex distributions in our study
population, the prevalence of AITD of approximately
11% is in line with previous results.6 13 26
One prior study, with a different design, has addressed
the question whether thyroid dysfunction relates to dis-
ease activity in RA.17 However, this was a cross-sectional
study in established RA using levels of thyroid-stimulating
hormone (TSH>4.2 µIU/mL) as the exposure, which was
present in 38% of the 52 prevalent RA patients. They
found higher disease activity parameters (DAS28 and
ESR) in patients with elevated TSH.
Our findings partly corroborate those of Emamifar
et al, of 439 RA patients with established RA, who com-
pared disease activity (DAS28-CRP) in RA patients with
and without hypothyroidism at treatment initiation. The
individual DAS28 components were not evaluated. Treat-
ment response measured as delta DAS28-CRP and
DAS28-CRP at 4 months was significantly lower among
RA-patients with thyroid disorders.18 We extend these
findings by demonstrating that they are mainly explained
by higher patient-related disease activity parameters at
baseline. Differences compared with our study include
the study design (patients were not defined as early RA,
the treatment was not restricted to methotrexate, thyroid
dysfunction was based on hospital records) and the statis-
tical approach.
Several susceptibility genes involved in the patho-
genesis of both AITD and RA have been identified,
including PTPN22 (protein tyrosine phosphatase non-
receptor type 22), CTLA4 (cytotoxic T-lymphocyte-
associated leucocyte antigen) and the HLA gene
Table 5 Association between autoimmune thyroid disease and response to methotrexate at 3-month follow-up visit among




AITD in good responders
(n)* (controls) OR (95% CI)† OR (95% CI)‡
Overall 376 (11) 286 (11) 0.95 (0.80–1.13) 0.93 (0.78–1.10)
Sex
Women 336 (14) 248 (15) 0.93 (0.78–1.12) 0.90 (0.75–1.08)
Men 40 (4) 38 (4) 1.05 (0.66–1.69) 1.03 (0.64–1.66)
Age group
<45 years 30 (9) 17 (6) 1.44 (0.76–2.76) 1.43 (0.74–2.75)
≥45 years 346 (11) 269 (11) 0.92 (0.77–1.10) 0.89 (0.75–1.07)
Serostatus
RF and/or ACPA positive 265 (11) 192 (11) 0.99 (0.81–1.22) 0.95 (0.78–1.17)
RF and ACPA negative 97 (10) 81 (10) 0.86 (0.62–1.20) 0.85 (0.60–1.18)
Serostatatus unspecified 14 (20) 13 (16) 1.19 (0.50–2.84) 1.49 (0.59–3.72)
*According to EULAR response criteria including imputed values on response status. Values are the numbers (%).
†Adjusted for age and sex.
‡Adjusted for age, sex, cortisone, HAQ, smoking. Multiple imputations=50.
AITD, autoimmune thyroid disease; HAQ, Health Assessment Questionnaire DisabilityIndex; RA, rheumatoid arthritis.
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complex including HLA-DRB1 (human leucocyte anti-
gen DR B1).
1 In addition, carriership of different
alleles of the HLA-DRB1 locus has been demonstrated
to be associated with anti-citrullinated protein antibo-
dies (ACPA)-positivity resulting in a more destructive
RA. One hypothesis is that shared susceptibility genes
could be one possible explanation to a potential lack
of treatment response in the younger (<45 years) sub-
group of patients. Individuals, who at young adult age
have already developed two autoimmune conditions,
potentially have a stronger shared inheritance.
Patient-reported parameters such as patient global,
VAS pain and HAQ could potentially be increased
due to symptoms such as fatigue, arthralgia and myal-
gia of a concurrent AITD. The different patterns in
disease activity over time and the lack of treatment
response seen in this limited subgroup of younger
patients compared with the whole population need
to be further investigated.
Our study has some limitations. We did not have
information on the presence of thyroid antibodies or
TSH levels. Thyroid antibodies have been reported
to be around 12% in the general population while
the prevalent of clinically overt AITD has been
reported to be lower.27 Taking other defined indica-
tions into account, thyroxine prescription has been
considered an accurate proxy for capturing clinically
overt AITD.6 22 Since we aimed to investigate the
impact of clinically overt AITD on RA disease activity
and treatment response we found this definition of
AITD adequate for our study. It cannot be ruled out
that some patients may have a non-autoimmune
cause for thyroxine treatment but this risk of
a potential misclassification must be viewed as having
at most marginal effect on our results. The patients
in our study were registered as rheumatoid factor
(RF) and/or ACPA positive in the SRQ, but we did
not have access to additional information on specific
auto-antibody profiles or titres. We did not have
information about other comorbidities potentially
associated with AITD.
Our study also has some strengths. The large sam-
ple size, approximately 9 000 included patients com-
pared 52 and 439 in previous studies, allowed us to
robustly investigate disease activity and treatment
response, also in subgroups. Furthermore, we used
prospectively recorded information on prescriptions
of thyroxine from the nationwide drug register, irre-
spective of RA response status, to minimise false-
negative comparisons and the risk of bias due to
selective recall, which is especially important in
such a common condition. We consider that the
large population-based sample size and the clinically
relevant definition of AITD make our findings gen-
eralisable to early RA patients in an international
perspective.
Achievement of disease control within 3–6 months
after initiation of RA-treatment has been shown to cor-
relate well with long-term outcome.28 Therefore, it is
important to identify potential outcome predictors,
and common co-morbidities in RA are important candi-
dates, that might capture differences in underlying
pathogenic mechanisms, which in turn may relate to
clinical disease activity. AITD is of special interest
there, since the symptoms of undertreated AITD may
overlap with RA symptoms. Based on our results, con-
comitant AITD only has marginal impact on disease
activity and response overall, but RA patients with
AITD do have somewhat higher patient reported out-
come measures at diagnosis, supporting that measures
that may reflect both conditions in a way (patient’s glo-
bal health, pain and function) can be higher in this
subgroup, thereby AITD does have an influence on the
phenotypic presentation of RA. In turn, this impacts the
treatment response criteria used in clinical practice. The
interpretation of treatment response should be seen in
this light. Thus, when treating and evaluating early RA
patients, those 10% with AITD in particular, it is of
importance to pay attention to not only to overall disease
activity and response measures such as DAS28 but to
unpick its components.
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